The Unit Economics Trap
Most pre-Series B genomics labs in India operate at ₹3,500–4,200 per report. This kills unit economics at scale. Series B requires ₹1,800–2,200 COGS to survive a 4–5x gross margin.
How? Automation of DNA extraction (robotic pipelines cut hands-on time 60%). Batch sequencing rather than per-sample runs. Negotiate reagent costs below ₹400 per genome (Illumina/BGI bulk pricing is real). Few founders track this monthly or own it operationally.
Investors will audit your last 100 samples. They'll ask: "What's your yield rate on first-pass sequencing?" If you stammer, they move on.
Regulatory Playbook Must Be Boring
One state ICMR approval is a pilot. Series B is 5+ states.
You need: Standard operating procedures for each lab environment (temperature, humidity, equipment calibration). Pre-approved consent templates for each state. Pre-negotiated rates with state health departments. A person who owns compliance full-time.
Telangana != Maharashtra != Tamil Nadu on sample transportation, data residency, and approval timelines. This isn't optional complexity. It's the moat.
We've seen genomics teams lose 8 weeks waiting for a second state approval because no one owned the paperwork. Series B investors will ask: "Show me your regulatory roadmap for the next 18 months." If it's vague, they'll reduce valuation 25–30%.
The Clinical Validation Moat
Sales teams optimize for speed. Clinical teams optimize for accuracy. In Series B, you need both, but separate.
You need a dedicated clinical team that:
- Validates every new gene panel against 500+ known variants before launch
- Runs quarterly reproducibility checks (same DNA sample, retested, verified against prior results)
- Owns the variant interpretation database (keep it internal, not outsourced)
- Sits in customer support calls when rare variants arise
This team shouldn't report to the VP Sales. This prevents rushing bad results to customers. Think of it like pharma QA—separate from manufacturing.
One recall due to a missed pathogenic variant costs ₹15–25 lakhs in retest credits and brand damage. Series B investors price this in.
The Team Depth Reality
Series A: you hire one lab director and hope. Series B: you hire functional heads.
You need:
- VP Operations (has run a CLIA-certified or ISO 15189–equivalent lab before)
- Head of Regulatory (has navigated ICMR, MoHFW, or state health approvals—state/central experience)
- Head of Clinical Affairs (MD or PhD with variant classification experience)
- VP Sales (with hospital/diagnostic channel track record in India)
If any role is filled by someone on a six-month contract or a second hat, your Series B narrative collapses. Investors ask: "Who owns quality if the VP Ops leaves?"
Board Dynamics Shift
Series A boards are permissive. Series B boards are operational.
Monthly board papers must include:
- Sample processing turnaround (target: <10 days)
- COGS per report (target: <₹2,200)
- Regulatory milestone progress (state approvals, timeline)
- Customer churn (genomics diagnostics should be <8% annual)
- NPS from hospital partners (target: >50)
If you show up without these metrics, the board will ask you to implement them before next month. This isn't strategy debate—it's operational hygiene.
The India Stack Lens
Digital payment adoption in Indian hospitals is now 35%. Lab connectivity to EMRs is weak but rising. Series B is the window to own integration before consolidators move in.
Your product must: integrate with top 5 hospital EMRs (Apollo, Max, Fortis systems), pipe results into patient dashboards (not PDFs), enable billing automation.
This requires a technical co-founder or CTO who understands healthcare APIs. Most genomics founders skip this. Investors notice.
The Closing Implication
Series B in genomics isn't about the science. It's about whether you can run the lab like a medical device factory, not a research project.
Clean operational metrics, regulatory templates for scale, clinical validation rigor, and a team with prior execution scars. These three things determine whether Series B closes at your target valuation or you get a 35% haircut.
Start fixing now. Series B investors already know this checklist.